Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.86 |
| ▸ | EBP | Q15125 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.56 |
| ▸ | MIF | P14174 | 2/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7623247 | 0.93 | ESR1 (0.75) | ESR1EBPSIGMAR1ESR2MIF | |
| SCHEMBL26957293 | 0.93 | ESR1 (1.00) | ESR1EBPSIGMAR1ESR2MIF | |
| SCHEMBL11821605 | 0.92 | ESR1 (0.72) | ESR1EBPSIGMAR1MIFCYP26A1 | |
| SCHEMBL7631805 | 0.89 | ESR1 (0.69) | ESR1EBPSIGMAR1ESR2MIF | |
| SCHEMBL20211881 | 0.86 | ESR1 (0.66) | ESR1EBPSIGMAR1ESR2CYP26A1 | |
| SCHEMBL7174574 | 0.85 | EBP (0.67) | ESR1EBPSIGMAR1ESR2MIF | |
| SCHEMBL5852043 | 0.85 | ESR1 (1.00) | ESR1EBPSIGMAR1ESR2 | |
| SCHEMBL8386622 | 0.85 | ESR1 (0.75) | ESR1ESR2CYP26A1 | |
| SCHEMBL2814712 | 0.85 | ESR1 (0.75) | ESR1ESR2CYP26A1 | |
| SCHEMBL29771211 | 0.84 | ESR1 (0.64) | ESR1EBPSIGMAR1ESR2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025119380-A1 | ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | 江苏威凯尔医药科技股份有限公司 | 2025-06-12 | — | — | WO | disclosed |
| CN-120118067-A | Estrogen receptor modulators and uses thereof | 江苏威凯尔医药科技股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2024141052-A1 | ESTROGEN-RECEPTOR MODULATOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118271284-A | Estrogen receptor modulators and uses thereof | 江苏威凯尔医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-10399939-B2 | Tetrahydronaphthalene estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399939-B2 | Tetrahydronaphthalene estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3374356-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017080966-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017080966-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| US-20170129855-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-6927224-B2 | Selective estrogen receptor modulators | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1417169-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20030105148-A1 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2003016270-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-0955286-B1 | Dihydro- or tetrahydronaphthalene derivatives having (anti-)estrogen activity | AVENTIS PHARMA SA (FR) | 2002-08-07 | — | — | EP | disclosed |
| US-6005003-A | OSTEOPOROSIS TREATMENT | HOECHST MARION ROUSSEL (FR) | 1999-12-21 | — | — | US | disclosed |
| EP-0955286-A1 | Dihydro- or tetrahydronaphthalene derivatives having (anti-)estrogen activity | HOECHST MARION ROUSSEL (FR) | 1999-11-10 | — | — | EP | disclosed |
| US-3947520-A | Compounds and process for preparing the same | THE UPJOHN COMPANY (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105148-A1 | Selective estrogen receptor modulators | ESR1, GPER1, PTGIR | ESR1 1/4885EBP 766/4885SIGMAR1 1089/4885 |
| US-10399939-B2 | Tetrahydronaphthalene estrogen receptor modulators and uses thereof | GPER1, ESR2, ESR1 | ESR1 3/4885EBP 152/4885SIGMAR1 712/4885 |
| US-20170129855-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GPER1, ESR2, ESR1 | ESR1 3/4885EBP 152/4885SIGMAR1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.